EP1851244A4 - Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon - Google Patents

Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon

Info

Publication number
EP1851244A4
EP1851244A4 EP05723079A EP05723079A EP1851244A4 EP 1851244 A4 EP1851244 A4 EP 1851244A4 EP 05723079 A EP05723079 A EP 05723079A EP 05723079 A EP05723079 A EP 05723079A EP 1851244 A4 EP1851244 A4 EP 1851244A4
Authority
EP
European Patent Office
Prior art keywords
antibody
cancer
agent
treatment
glycosylation variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05723079A
Other languages
English (en)
French (fr)
Other versions
EP1851244A1 (de
Inventor
Scott E Strome
Daniel Schindler
Lieping Chen
Harry Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Priority to EP11173253A priority Critical patent/EP2399935A3/de
Publication of EP1851244A1 publication Critical patent/EP1851244A1/de
Publication of EP1851244A4 publication Critical patent/EP1851244A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05723079A 2005-02-15 2005-02-15 Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon Withdrawn EP1851244A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11173253A EP2399935A3 (de) 2005-02-15 2005-02-15 Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/004739 WO2006088447A1 (en) 2005-02-15 2005-02-15 An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof

Publications (2)

Publication Number Publication Date
EP1851244A1 EP1851244A1 (de) 2007-11-07
EP1851244A4 true EP1851244A4 (de) 2009-04-15

Family

ID=36916751

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11173253A Withdrawn EP2399935A3 (de) 2005-02-15 2005-02-15 Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon
EP05723079A Withdrawn EP1851244A4 (de) 2005-02-15 2005-02-15 Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11173253A Withdrawn EP2399935A3 (de) 2005-02-15 2005-02-15 Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon

Country Status (2)

Country Link
EP (2) EP2399935A3 (de)
WO (1) WO2006088447A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568433A (en) * 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2012201010B2 (en) * 2005-10-21 2015-01-22 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
NZ607710A (en) 2010-09-09 2014-11-28 Pfizer 4-1bb binding molecules
CA3019531A1 (en) * 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP3594230A1 (de) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies In hohem masse galactosylierte anti-tnf-alpha-antikörper und verwendungen davon
RU2016146993A (ru) * 2014-05-21 2018-06-21 Пфайзер Инк. Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака
JP2018508509A (ja) * 2015-02-22 2018-03-29 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ１３７に結合する抗体医薬
WO2016185016A1 (en) 2015-05-21 2016-11-24 Alligator Bioscience Ab Novel polypeptides
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
JP6845846B6 (ja) * 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
EP3472206B1 (de) 2016-06-20 2025-01-15 invoX Pharma Limited Lag-3-bindende elemente
WO2018121787A1 (en) * 2016-12-30 2018-07-05 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd137
CN108424928B (zh) 2016-12-30 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
CN112867733B (zh) * 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 抗cd137抗体及其应用
WO2021226883A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer submission of sequence listing on ascii text file

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016249A1 (en) * 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
WO2000029445A1 (en) * 1998-11-17 2000-05-25 Lg Chemical Limited Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
WO2003049755A1 (en) * 2001-10-09 2003-06-19 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US20040025193A1 (en) * 2002-08-01 2004-02-05 Yann Echelard Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer
WO2004010947A2 (en) * 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016249A1 (en) * 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
WO2000029445A1 (en) * 1998-11-17 2000-05-25 Lg Chemical Limited Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
WO2003049755A1 (en) * 2001-10-09 2003-06-19 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
WO2004010947A2 (en) * 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US20040025193A1 (en) * 2002-08-01 2004-02-05 Yann Echelard Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
HORAN-HAND P ET AL: "COMPARATIVE BIOLOGICAL PROPERTIES OF A RECOMBINANT CHIMERIC ANTI-CARCINOMA MAB AND A RECOMBINANT AGLYCOSYLATED VARIANT", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 35, no. 3, 1992, pages 165 - 174, XP001539281, ISSN: 0340-7004 *
HUMPHREYS D P ET AL: "THERAPEUTIC ANTIBODY PRODUCTION TECHNOLOGIES: MOLECULES, APPLICATIONS, EXPRESSION AND PURIFICATION", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 4, no. 2, 1 March 2001 (2001-03-01), pages 172 - 185, XP008016086, ISSN: 1367-6733 *
MEADE H M ET AL: "Expression of recombinant proteins in the milk of transgenic animals", GENE EXPRESSION SYSTEMS. USING NATURE FOR THE ART OF EXPRESSION, XX, XX, 1 January 1999 (1999-01-01), pages 399 - 427, XP009088286 *
OKAZAKI A ET AL: "Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcgammaRIIIa", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 336, no. 5, 5 March 2004 (2004-03-05), pages 1239 - 1249, XP004490178, ISSN: 0022-2836 *
POLLOCK D P ET AL: "Transgenic milk as a method for the production of recombinant antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 147 - 157, XP004186081, ISSN: 0022-1759 *
See also references of WO2006088447A1 *
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002495886, ISSN: 0021-9258, [retrieved on 20001128], DOI: 10.1074/JBC.M009483200 *
SHIELDS ROBERT L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002442140, ISSN: 0021-9258 *
W. LIN ET AL: "Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies", BLOOD, vol. 112, no. 3, 1 August 2008 (2008-08-01), pages 699 - 707, XP055037053, ISSN: 0006-4971, DOI: 10.1182/blood-2007-11-122465 *
WRIGHT A ET AL: "EFFECT OF ALTERED CH2-ASSOCIATED CARBOHYDRATE STRUCTURE ON THE FUNCTIONAL PROPERTIES AND IN VIVO FATE OF CHIMERIC MOUSE-HUMAN IMMUNOGLOBULIN G1", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 180, no. 3, 1 September 1994 (1994-09-01), pages 1087 - 1096, XP000676306, ISSN: 0022-1007 *
ZHOU Q ET AL: "Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 117, no. 1, 20 April 2005 (2005-04-20), pages 57 - 72, XP004836787, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
EP2399935A3 (de) 2012-02-22
WO2006088447A1 (en) 2006-08-24
EP1851244A1 (de) 2007-11-07
EP2399935A2 (de) 2011-12-28

Similar Documents

Publication Publication Date Title
EP1851244A4 (de) Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon
CY2016031I1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY2017013I1 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
EP1392818A4 (de) Zur behandlung von krebserkrankungen beim menschen geeigneter chimärer immunrezeptor
EP2279003A4 (de) Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
EP1793858A4 (de) Menschliche monoklonale anti-ctla4-antikörper zur krebsbehandlung
IL231077A0 (en) Pharmaceutical compositions comprising a pd-1 antagonist for treating infections and tumors
EP1711191A4 (de) Chlorit bei der behandlung neurodegenerativer krankheiten
IL222880A (en) Peptides and their use in the treatment and diagnosis of diseases and pharmaceutical preparations containing them
EP2011513A4 (de) Therapeutische mittel gegen alzheimer-krankheit und krebs
EP1848995A4 (de) Wasserlösliche nanokristalle und verfahren zur herstellung davon
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
EE200300474A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
ITBS20040068A1 (it) Composizione cosmetica e/o farmaceutica per il trattamento della rosacea
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
EP1720893A4 (de) Zusammensetzungen und verfahren zur systemischen behandlung von arthritis
FR2825279B1 (fr) Medicament utile dans le traitement du cancer
FR2903999B1 (fr) Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
DE112004001618D2 (de) Pharmazeutischer Wirkstoff gegen Tumorerkrankungen
FR2883182B1 (fr) Composition de vitamines utiles dans le traitement des maladies oculaires
EP1613585A4 (de) Verbindungen und verfahren zur verwendung bei der behandlung von neoplasmen und krebs, basierend auf inhibitoren von isoprenylcysteinmethyltransferase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090317

17Q First examination report despatched

Effective date: 20090629

DAC Divisional application: reference to earlier application (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130319